Sign In
Buy MREO
$0.334
-0.0052 (-1.53%)
At Close: Jun 03, 2026
Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points
01:36pm, Tuesday, 26'th Nov 2024
Mereo BioPharma Group plc's setrusumab shows promise in treating osteogenesis imperfecta, with phase 3 studies fully enrolled and potential for multiple catalysts in 2025. Positive 14-month data from
Verde Reports up to 13,944 ppm TREO 5,222 ppm MREO and 213 ppm DyTb
07:00am, Monday, 18'th Nov 2024
Results from 16 new holes show a thick mineralized zone up to 74m with grades up to 4,321 ppm TREO and 1,004 ppm MREO Results from 16 new holes show a thick mineralized zone up to 74m with grades up t
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
07:30am, Thursday, 14'th Nov 2024
LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announ
Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
07:30am, Tuesday, 12'th Nov 2024
Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mereo
Verde's assays of over 1,500m of drilling find rare earths up to 12,487 ppm TREO and 3,357 ppm MREO
07:15am, Tuesday, 29'th Oct 2024
Results from 13 new holes show an 89m thick mineralized zone with grades up to 3,706 ppm TREO and 839 ppm MREO Results from 13 new holes show an 89m thick mineralized zone with grades up to 3,706 ppm
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference
05:35pm, Thursday, 12'th Sep 2024
LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today annou
Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
08:00am, Tuesday, 13'th Aug 2024
Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase 2 data from the Phase 2/3 Orbit study demonstrated continued reduction in
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announ
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
07:30am, Thursday, 30'th May 2024
LONDON, May 30, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announc
Equities Analysts Offer Predictions for Mereo BioPharma Group plc’s Q2 2024 Earnings (NASDAQ:MREO)
01:38am, Monday, 20'th May 2024
Mereo BioPharma Group plc (NASDAQ:MREO – Free Report) – Equities researchers at Leerink Partnrs issued their Q2 2024 earnings per share estimates for shares of Mereo BioPharma Group in a r
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
04:01pm, Wednesday, 15'th May 2024
LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announc
MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Friday, 12'th Apr 2024
The heavy selling pressure might have exhausted for MEREO BIOPHARMA (MREO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ana
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
07:30am, Wednesday, 03'rd Apr 2024
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today annou
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
04:01pm, Wednesday, 27'th Mar 2024
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively
Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032
05:34pm, Thursday, 14'th Mar 2024
Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation th
